NIDDK to hold the (NIH) Phase II trial

Recent information on clinicaltrials.gov lets us know that it's NIDDK (The National Institute of Diabetes and Digestive and Kidney) who will conduct the Phase II trial.

126 patients will be enrolled.

• 42 patients: two injections of Diamyd 20ug vaccine 4 weeks apart, and the third 8 weeks after the second.
• 42 patients: two injections of Diamyd 20ug vaccine 4 weeks apart, and a placebo injections as the last one 8 weeks after the second.
• 42 patients: three injections of placebo as a control.
  

Primary endpoint is C-Peptide.

To be eligible for this trial you need to be between 8-45 years old, and diagnosed within the previous 3 months.

ClinicalTrials identifier for this trial: NCT00529399

Take care!